GSK veteran Dave Tudor joins MMIC in Scotland
pharmafile | November 9, 2018 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | GSK, Scotland, dave tudor, life sciences, manufacturing
GlaxoSmithKline veteran, Dave Tudor, is set to take on the role of Managing Director of the Medicines Manufacturing Innovation Centre (MMIC), a new manufacturing centre designed to increase the speed and cost effectiveness of the process through which medicines are brought to market. The facility is set to be built in Renfrewshire, Scotland over the next two years.
The new centre, which will be located at the Advanced Manufacturing Innovation Centre near Glasgow Airport, will see the creation of 80 new, high value jobs. It is hoped that the centre will attract more than £80 million in investment by 2028.
Dr Tudor, who graduated with a PhD in Chemistry from the University of Glasgow in 1992, joined SmithKline Beecham in the same year. Following his entry into the firm, the GSK and Life Sciences Scotland Industry Leadership Group head held a variety of chemical development posts within the company before becoming section head in 1995.
Since joining GSK Tudor has taken on roles of increasing seniority before becoming VP, Head of Supply Chain Strategy in 2017. Although he resides in Scotland, the experienced pharma professional has worked across the globe.
Tudor, a resident Scot, commented: “I’m excited to have the chance to create a transformative strategy for life sciences in the UK. What really motivates me is the idea that we can avoid waste, reduce costs and make these medicines more accessible and more affordable. Anything that can be done to transform the product and make it cheaper has got to be a good thing.”
Tudor’s new role will see him seek to facilitate collaboration between members of the MMIC which includes companies such as AstraZeneca and GSK.
Nigel Perry, chief executive officer (CEO) at Centre for Process Innovation, who run the project, commented: “I’m extremely proud to welcome Dave Tudor to our team here at CPI. I am confident he will help the MMIC modernise the pharmaceutical industry’s approach to clinical development and commercial manufacture to help make healthcare more affordable.”
Related Content
GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …
Chemify relocates to Glasgow’s new Health Innovation Hub
The company will be one of the first tenants in the city’s flagship life sciences …
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
